|
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension
|
Ongoing
|
Interferon beta-1a
|
3
|
105MS306
|
KFSH&RC-J
|
|
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
|
Terminated
|
NIVOLUMAB IPILIMUMAB
|
3
|
CA209-227
|
KFSH & RC-R
|
|
An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients
|
Completed
|
Travoprost 0.004%
|
1
|
C-12-009
|
KKESH
|
|
"An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP). "
|
Completed
|
Asfotase Alfa
|
2
|
ENB-010-10
|
KFSH & RC-R
|
|
An open-Label, multicenter, expanded access study of Everolimus in Patients with advanced Nerouendocrine tumors.
|
Completed
|
Everolimus
|
3b
|
CRAD001K24133
|
KFSH & RC-R
|
|
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)
|
Ongoing
|
ABT-450/r/ABT-267+ABT-333 (-/+) Ribavirin (RBV)
|
3b
|
M14-423
|
KKUH
|
|
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)
|
Ongoing
|
A4250
|
3
|
A4250-008
|
KFSH&RC-R
|
|
"An open-label extension study of the long-term safety, tolerability and efficacy of Ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension(CTEPH)."
|
Completed
|
Ambrisentan
|
3
|
116457
|
KFMC
|
|
AN OPEN LABEL, SINGLE ARM, MULTICENTER,SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT
|
Completed
|
Atezolizumab (MPDL3280A; RO5541267)
|
3
|
MO29983
|
KFSH & RC-R
|
|
An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
|
Completed
|
Sebelipase alfa (SBC-102)
|
2
|
LAL-CL03
|
KFSH & RC-R
|
